Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis Report 2025

Prostate cancer is the most common cancer affecting the male population in the United States. The incidence is 70% higher in black men as compared to whites. The incidence of metastatic castration-resistant prostate cancer (an advanced state of this cancer) is increasing at an alarming rate of 5% every year. Therefore, there is an emphasis on developing high-quality and potent drugs for the disease.

Report Coverage

The Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Insight Report by the publisher gives comprehensive insights into metastatic castration-resistant prostate cancer drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Metastatic castration-resistant prostate cancer. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic castration-resistant prostate cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from metastatic castration-resistant prostate cancer.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to metastatic castration-resistant prostate cancer.

Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Outlook

Metastatic castration-resistant prostate cancer is an advanced state of prostate cancer that has spread to other parts of the body such as lymph nodes, rectum, liver, lungs or bones. In this state of cancer, the body stops responding to hormone treatment that is responsible for lowering testosterone levels and slowing down disease progression in patients. Signs and symptoms may depend on tumor size and areas where it has spread. Pain or blood while urinating, shortness of breath, fatigue and weight loss are common symptoms. Although androgen deprivation therapy (ADT) or hormone therapy may not work, patients are still kept on these therapies as there is a chance that some cancerous cells may respond to them. Other treatment alternatives involve chemotherapy, immunotherapy, radioactive materials, and others.

To combat the rising mortality and comorbidity rate associated with the disease, several drugs have been approved by the FDA in 2023. For instance, in August 2023, a combination of niraparib and abiraterone acetate tablets (Akeega) with prednisone received the FDA’s green signal. In addition, the combination Talazoparib (a PARP inhibitor) and enzalutamide received FDA approval and a marketing authorisation by the EMA in June 2023.

Metastatic Castration-Resistant Prostate Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of metastatic castration-resistant prostate cancer drugs based on several segmentations including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The pipeline assessment report covers 50+ drug analyses based on drug classes:

• Androgen Receptor Signal Inhibitors
• CYP17 Inhibitors
• Chemotherapy
• Immunotherapy
• Bone-Targeted Therapy
• Radiopharmaceuticals

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Metastatic Castration-Resistant Prostate Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for metastatic castration-resistant prostate cancer. There are around 509 drugs in phase II of metastatic castration-resistant prostate cancer drugs.

Metastatic Castration-Resistant Prostate Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under metastatic castration-resistant prostate cancerpipeline analysis include androgen receptor signal inhibitors, CYP17 inhibitors, chemotherapy, immunotherapy, bone-targeted therapy and radiopharmaceuticals. Treatment strategies are decided on the basis of multiple factors such as side effects and the overall health of the patients.

Metastatic Castration-Resistant Prostate CancerClinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the metastatic castration-resistant prostate cancer drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in metastatic castration-resistant prostate cancer clinical trials:

• AstraZeneca
• SpectronRX
• Hoffmann-La Roche
• Pfizer
• Bayer
• Janssen Research & Development, LLC
• Ipsen
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sanofi
• Merck Sharp & Dohme LLC

Metastatic Castration-Resistant Prostate Cancer- Emerging Drugs Profile

JNJ-78278343

Sponsored by Janssen Research & Development, LLC, JNJ-78278343 is being investigated to treat metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate. The drug is in Phase 1 study and will be administered in combination with either Taxane chemotherapy, Cetrelimab (JNJ-63723283) or androgen receptor pathway inhibitors.

AMG 340

Amgen's AMG 340 is being evaluated to treat metastatic castration resistant prostate cancer. This PSMAxCD3 T-cell engaging bispecific antibody is in Phase 1 of an open-label study with 2 arms, namely, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B).

BMS-986460

This drug is under investigation to treat metastatic castration resistant prostate in adults. Sponsored by Bristol-Myers Squibb, the drug is in Phase 1 of an open-label study with 90 enrolled participants.

Carfilzomib

Researchers at the University of Alabama at Birmingham are evaluating Carfilzomib for its efficacy against metastatic castration-resistant prostate cancer (CRPC). Previously approved for multiple myeloma treatment, the drug is being assessed to reduce prostate cancer progression in patients who have received chemotherapy and androgen inhibitors in the past. It is currently in Phase 2 of the trial.

Reasons To Buy This Report

The Metastatic Castration-Resistant Prostate Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for metastatic castration-resistant prostate cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within metastatic castration-resistant prostate cancer pipeline insights.

Key Questions Answered in the Metastatic Castration-Resistant Prostate Cancer- Pipeline Insight Report

• What is the current landscape of metastatic castration-resistant prostate cancer pipeline drugs?
• How many companies are developing metastatic castration-resistant prostate cancer drugs?
• How many phase III and phase IV drugs are currently present in metastatic castration-resistant prostate cancer pipeline drugs?
• Which companies/institutions are leading the metastatic castration-resistant prostate cancer drug development?
• What is the efficacy and safety profile of metastatic castration-resistant prostate cancer pipeline drugs?
• What are the opportunities and challenges present in the metastatic castration-resistant prostate cancer drug pipeline landscape?
• Which company is conducting major trials for metastatic castration-resistant prostate cancer drugs?
• What geographies are covered for metastatic castration-resistant prostate cancer clinical trials?
• What are emerging trends in metastatic castration-resistant prostate cancer clinical trials?

Related Reports

Castrate-Resistant Prostate Cancer Market

Global Prostate Health Market

Global Clinical Trials Market

This product will be delivered within 3-5 business days.